Page last updated: 2024-08-25

rosiglitazone and Alveolar Bone Atrophy

rosiglitazone has been researched along with Alveolar Bone Atrophy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alves, JB; Alves, PM; Campos-Júnior, JC; Cunha, FQ; Gonçalves, RB; Hassumi, MY; Kawai, T; Napimoga, MH; Silva-Filho, VJ; Vieira, SM1
Britti, D; Cuzzocrea, S; De Majo, M; Di Paola, R; Genovese, T; Maiere, D; Mazzon, E; Zito, D1

Other Studies

2 other study(ies) available for rosiglitazone and Alveolar Bone Atrophy

ArticleYear
PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis.
    International immunopharmacology, 2009, Volume: 9, Issue:10

    Topics: Acid Phosphatase; Administration, Oral; Alveolar Bone Loss; Animals; Cell Differentiation; Cell Line; Hypoglycemic Agents; Immunohistochemistry; Isoenzymes; Male; Osteoclasts; Osteogenesis; Periodontitis; PPAR gamma; RANK Ligand; Rats; Rats, Wistar; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazolidinediones

2009
Rosiglitazone reduces the evolution of experimental periodontitis in the rat.
    Journal of dental research, 2006, Volume: 85, Issue:2

    Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ligation; Male; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Periodontitis; Poly(ADP-ribose) Polymerase Inhibitors; PPAR gamma; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Tyrosine

2006